MorphoSys AG: GSK, MorphoSys' Licensing Partner, Provides Up

MorphoSys AG: GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner, GSK plc (GSK), provided an update on the ContRAst phase III program

Related Keywords

Germany , Boston , Massachusetts , United States , Planegg , Bayern , Thomas Biegi , Julia Neugebauer , Eamonn Nolan , Morphosys Agview , Exchange Commission , Linkedin , Twitter , American College Of Rheumatology , American College , Janus Kinase , Morphosy Annual Report , Morphosys , Icensing , Partner , Rovides , Update , Contrast , Hase , Program , Otilimab , Moderate , Evere , Rheumatoid , Arthritis ,